Lear (LEA) Margin Compression Challenges Bullish Earnings Growth Narrative

Advertisement

Lear’s FY 2025 Earnings in Focus

Lear (LEA) has wrapped up FY 2025 with fourth quarter revenue of US$5.99b and basic EPS of US$1.55, while trailing twelve month revenue came in at US$23.26b with basic EPS of US$8.15. Over recent periods the company has seen quarterly revenue move between US$5.56b and US$6.03b, with basic EPS ranging from US$1.50 to US$3.07. This gives investors a clearer view of how top line scale and per share earnings have paired up through the year. With net income margins sitting in the low single digits and earnings growth expectations in the spotlight, this set of results highlights profitability and how much of that revenue drops to the bottom line for investors.

See our full analysis for Lear.

With the latest numbers on the table, the next step is to see how they line up against the widely followed narratives around Lear’s growth potential, margin quality and overall risk reward profile.

Curious how numbers become stories that shape markets? Explore Community Narratives

NYSE:LEA Earnings & Revenue History as at Feb 2026
NYSE:LEA Earnings & Revenue History as at Feb 2026

Margins Tighten With 1.9% Net Profit Level

  • On a trailing basis, Lear generated US$23.26b of revenue and US$436.8 million of net income, which works out to a 1.9% net profit margin compared with 2.2% in the prior year.
  • What stands out for the bullish view that talks up high quality earnings is that this 1.9% margin sits alongside forecast earnings growth of 34.68% per year, so investors are weighing:
    • Trailing EPS on a last twelve month basis of US$8.15 and net income of US$436.8 million, set against expectations for much faster profit growth than the 1.7% forecast revenue growth rate.
    • The recent margin slip from 2.2% to 1.9%, which means the strong earnings growth outlook needs either better margins or added efficiency on roughly similar revenue growth to fully support the bullish case.
📊 Read the full Lear Consensus Narrative.

EPS Swings Across FY 2025

  • Across FY 2025, basic EPS moved between US$1.50 in Q1 and US$3.07 in Q2, while quarterly net income ranged from US$80.7 million to US$165.2 million on revenue that stayed in a fairly tight band of about US$5.6b to US$6.0b.
  • Consensus style optimism around earnings growth is partly challenged by this pattern, because:
    • Last twelve month basic EPS eased from US$9.56 at 2024 Q3 to US$8.15 at 2025 Q4, even though quarterly revenue stayed near US$6.0b, showing that recent profit per share has not moved in the same direction as the upbeat 34.68% earnings growth forecast.
    • The mix of a strong Q2 EPS of US$3.07 and a Q4 EPS of US$1.55 suggests earnings have been uneven within the year, which may lead some investors to question how smooth that forecast growth path might be.

Discounted Multiples And DCF Gap

  • At a share price of US$132.45, Lear trades on a trailing P/E of 15.7x, below both the peer average of 30.6x and the US auto components industry average of 24.3x, and about 11% below the DCF fair value of US$148.74.
  • The optimistic narrative that sees value in the name is heavily supported on the numbers, but there are trade offs to keep in mind:
    • The combination of a P/E discount to peers and industry, plus the 11% gap to DCF fair value, lines up with the view that investors are not paying up for the forecast 34.68% earnings growth rate.
    • At the same time, the 1.9% trailing net margin and description of an unstable dividend record give a concrete reason why some investors might hesitate to close that valuation gap quickly, even with the apparent discount in place.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Lear's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

See What Else Is Out There

Lear’s low 1.9% net margin, easing trailing EPS and uneven quarterly earnings highlight that profitability and earnings consistency are pressure points in the current story.

If you want companies where revenue and earnings tend to move more steadily, check out stable growth stocks screener (2188 results) to focus on names with a clearer, smoother growth profile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NYSE:LEA

Lear

Designs, develops, engineers, manufactures, assembles, and supplies automotive seating, and electrical distribution systems and related components for automotive original equipment manufacturers in North America, Europe, Africa, Asia, and South America.

Undervalued with excellent balance sheet and pays a dividend.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
48 users have followed this narrative
2 users have commented on this narrative
8 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
186 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0